anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods for changing the delivery of an active ingredient to the vasculature of an animal by iontophoresis have the steps of adding a vasoactivator to a formulation with an active ingredient, coiontophoresing the vasoactivator and the active ingredient into the skin of an animal and establishing a concentration of the vasoactivator in the skin near the upper capillary loops thereof so that the blood flow is changed therethrough. The vasoactivator effectively changes the blood flow in the upper capillary loops of the vasculature in the skin of an animal. If the vasoactivator is a vasodilator, the blood flow is increased and when the vasoactivator is a vasoconstrictor, the blood flow is decreased. An iontophoretic delivery apparatus for use with a formulation for controlling iontophoretic transdermal administration of an active ingredient into the blood stream of the vasculature of an animal has a donor reservoir and an indifferent reservoir with an electric field therebetween for the flow of ions thereacross. The formulation is associated with the donor reservoir for coiontophoresis along the electric field to the indifferent reservoir. The vasoactivator in the formulation changes the blood flow in the upper capillary loops controlling the introduction of the active ingredient into the blood stream of the animal. A composition for coiontophoretic delivery has a solution of an active ingredient and a vasoactivator in a polar liquid.
People with CF often have lung infections that occur repeatedly or worsen over time. The lung infections are often caused by PA. Treatment with antibiotics is used to reduce the presence of the bacteria. The antibiotics may be given orally, intravenously, or inhaled as a mist. The purpose of this study was to evaluate whether AZLI, an investigational formulation of the antibiotic aztreonam, is safe in repeated courses in patients with CF and PA.

A course of AZLI treatment in this study comprised 28 days, followed by a 28-day period off treatment. Participants could receive up to 9 courses of AZLI, with a total time on study of up to 18 months. Safety and efficacy results for the 18-month, 9-course period are reported, with efficacy results presented on a by-treatment course basis.
PURPOSE:To provide the subject preventive and remedy containing a thiamulin derivative as an active component, exhibiting excellent antibacterial activity against bacteria of genus Renibacterium such as streptococci and free from cross-resistance between various conventional antibiotic substances. CONSTITUTION:The objective agent contains thiamulin or a thiamulin derivative selected from acid addition salt and quaternary salt of thiamulin, e.g. thiamulin fumarate, as an active component. The thiamulin derivative can be synthesized by the chemical modification of a precursor pleuromutilin which is a diterpene antibiotic substance derived from the filtrate of culture liquid of Pleurotus mutilus, The agent is administered in the form of powder, liquid, feed, etc., preferably by mixing with a diluent (e.g. starch or salt), excipient, etc., at a dose of preferably 1-500ppm. It is useful for the prevention and remedy of bacterial disease of fish such as streptococciosis and bacterial kidney disease.
The control group will complete a demographics questionnaire and knowledge survey. Participants will subsequently view the 10-minute Safe Sleep for your Baby (SIDS) educational video. It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome. This will be around the time of the newborn hearing screening. Participants will complete the knowledge survey again before discharge, and after approximately four to six weeks.
Dental calculus severely affects the oral health of humans and animal pets. Calculus deposition affects the gingival appearance and causes inflammation. Failure to remove dental calculus from the dentition results in oral diseases such as periodontitis. Apart from adversely affecting oral health, some systemic diseases are closely related to dental calculus deposition. Hence, identifying the mechanisms of dental calculus formation helps protect oral and systemic health. A plethora of biological and physicochemical factors contribute to the physiological equilibrium in the oral cavity. Bacteria are an important part of the equation. Calculus formation commences when the bacterial equilibrium is broken. Bacteria accumulate locally and form biofilms on the tooth surface. The bacteria promote increases in local calcium and phosphorus concentrations, which triggers biomineralization and the development of dental calculus. Current treatments only help to relieve the symptoms caused by calculus deposition. These symptoms are prone to relapse if calculus removal is not under control. There is a need for a treatment regime that combines short-term and long-term goals in addressing calculus formation. The present review introduces the mechanisms of dental calculus formation, influencing factors, and the relationship between dental calculus and several systemic diseases. This is followed by the presentation of a conceptual solution for improving existing treatment strategies and minimizing recurrence.
Using CD28-specific super agonistic monoclonal antibodies (mAb) or their mimicry compounds (A) for preparing a pharmaceutical composition (I) for treatment or prophylaxis of autoimmune mediated inflammatory diseases or immune regeneration, is new. Using CD28-specific super agonistic monoclonal antibodies (mAb) or their mimic compounds (A) for preparing a pharmaceutical composition (I) for treatment or prophylaxis of autoimmune mediated inflammatory diseases or immune regeneration, is new. (I), under standard conditions, is prepared so that the dose of mAb lies below a defined first border dose when the treatment or prophylaxis of autoimmune inflammatory disease is indicated and the dose of mAb lies above a defined second border dose when the immune reconstitution is indicated. An independent claim is also included for treating or prophylaxis of autoimmune mediated inflammatory diseases comprising: (a) administering (I) (containing (A) and galenic preparation for a definite and applied pharmaceutical form), preferably via intravenous injection, to a patient; or (b) removing a body fluid (preferably blood) containing T-lymphocytes or their precursor cells, treating with (by appropriate process) (A) and administering thus treated body fluid (preferably via intravenous injection) to the patient. ACTIVITY : Antiinflammatory; Immunosuppressive; Antiarthritic; Antirheumatic; Neuroprotective; Antidiabetic; Antipsoriatic; CNS-Gen.; Cytostatic; Anti-HIV; Virucide. No biological data is given. MECHANISM OF ACTION : Cluster of differentiation-28 (CD28) specific super agonist.
Research demonstrates the important role of genetic factors in attention-deficit/hyperactivity disorder (ADHD). DNA sequencing of families provides a powerful approach for identifying de novo (spontaneous) variants, leading to the discovery of hundreds of clinically informative risk genes for other childhood neurodevelopmental disorders. This approach has yet to be extensively leveraged in ADHD. We conduct whole-exome DNA sequencing in 152 families, comprising a child with ADHD and both biological parents, and demonstrate a significant enrichment of rare and ultra-rare de novo gene-damaging mutations in ADHD cases compared to unaffected controls. Combining these results with a large independent case-control DNA sequencing cohort (3206 ADHD cases and 5002 controls), we identify lysine demethylase 5B (KDM5B) as a high-confidence risk gene for ADHD and estimate that 1057 genes contribute to ADHD risk. Using our list of genes harboring ultra-rare de novo damaging variants, we show that these genes overlap with previously reported risk genes for other neuropsychiatric conditions and are enriched in several canonical biological pathways, suggesting early neurodevelopmental underpinnings of ADHD. This work provides insight into the biology of ADHD and demonstrates the discovery potential of DNA sequencing in larger parent-child trio cohorts.
In addition to routine NDT training, Structured Exergame Program for upper extremity and trunk control will be applied in this group. Xbox one - Kinect supported video games will be selected for video-game based exergame program. The Video games to be included in the Exergame program will be selected by Analytical Hierarchy Process. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
Disclosed is a computer-implemented method of determining a treatment plan, encompassing acquiring patient image data, acquiring target data describing targets, acquiring position data describing control points which define one or more arcs, and determining target projection data which describes outlines of the target in a beam's- eye view. Margin data is acquired. For the outlines, margins are applied to determine auxiliary outlines. Beam shaping device data is determined describing configurations of the collimator leaves so that irradiation of the auxiliary outlines is enabled. Based on these configurations, the irradiation amount is simulated for voxels of the patient image data. Constraints to be fulfilled by the treatment plan may be set. Configurations of blockings, arc-weights and margins are proposed. Only different combinations of these parameters are proposed while additional possible parameters are neglected. An optimization algorithm is used to minimize an objective function. The best configuration is selected as the treatment plan.
AIM: Medical therapy with antibiotics only and surgical drainage are the treatment options of tubo-ovarian abscess (TOA). It is not yet known exactly which cases need surgical treatment. The aim of this systematic review and meta-analysis was to evaluate the risk factors leading antibiotic therapy failure in women with TOA.
METHODS: We searched the following databases from inception to June 1, 2022: PubMed, Ovid MEDLINE, The Cochrane Library, and Scopus. We also searched reference lists of eligible articles and related review articles. The observational cohort, cross-sectional, and case-control studies were included in the meta-analysis. At least four review authors independently selected eligible articles, assessed risk of bias, and extracted data. The random effect model was used in the meta-analysis.
RESULTS: A total of 29 studies, including 2890 women, were included in the study. The age, abscess size, history of intrauterine device use, postmenopausal status, history of diabetes mellitus, fever, white blood cell count, erythrocyte sedimentation rate, C-reactive protein level, and history of pelvic inflammatory disease were found as significant risk factors for antibiotic therapy failure in women with TOA.
CONCLUSIONS: The findings of this study clarified the risk factors for antibiotic therapy failure in women with TOA.
The objective of this study is to compare gastric emptying assessed by the modified 13C spirulina breath test and scintigraphy in 30 subjects, i.e., 15 healthy subjects and 15 with dyspepsia. Gastric emptying will be simultaneously assessed by both methods using a dual-labeled meal. It is anticipated that the gastric emptying half-time (t½) values based on the 13C breath excretion values will compare with the gold standard, scintigraphy, in which the "true" t½ values are obtained. The aims of this study are to estimate factors necessary for converting exhaled 13C concentrations to gastric emptying half-time, as measured by scintigraphy, in healthy subjects and patients with dyspepsia.

For each potential participant, a screening visit will be conducted within 4 weeks prior to the study visit. During the screening visit, informed consent will be obtained, and a physical exam will be conducted by a trained investigator. Participants will then be free to leave the test site. A urine pregnancy test for women of child-bearing potential will be completed within 48 hours prior to exposure to radiation. After an overnight (minimum 8 hour) fast, the participants will return to the study center, at which time the dual-label Gastric Emptying Test will be administered. A baseline breath sample will be collected in duplicate by having the subject blow through a straw into a collection tube. The test meal will be prepared by personnel at the test site after the subject arrives. Step-by-step test meal preparation instructions are provided with the GEBT kit. The patient will consume the test meal containing \[13C\]-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.

As the cooked egg is triturated by the stomach, it passes through the pylorus into the intestine where the \[13C\]-Spirulina platensis is digested, absorbed, and metabolized giving rise to labeled carbon dioxide expired in the breath. Breath samples, collected before and after the test meal, are shipped overnight to Advanced Breath Diagnostics for analysis by Gas Isotope Ratio Mass Spectroscopy. By measuring the change in excretion over time, the rate of gastric emptying can be determined.
BACKGROUND: Resuscitative endovascular balloon occlusion of the aorta (REBOA) has been often used in place of open aortic occlusion for management of hemorrhagic shock in trauma. There is a paucity of data evaluating REBOA usage in military settings.
STUDY DESIGN AND METHODS: We queried the Department of Defense Trauma Registry (DODTR) for all cases with at least one intervention or assessment available within the first 72 h after injury between 2007 and 2023. We used relevant procedural codes to identify the use of REBOA within the DODTR, and we used descriptive statistics to characterize its use.
RESULTS: We identified 17 cases of REBOA placed in combat settings from 2017 to 2019. The majority of these were placed in the operating room (76%) and in civilian patients (70%). A penetrating mechanism caused the injury in 94% of cases with predominantly the abdomen and extremities having serious injuries. All patients subsequently underwent an exploratory laparotomy after REBOA placement, with moderate numbers of patients having spleen, liver, and small bowel injuries. The majority (82%) of included patients survived to hospital discharge.
DISCUSSION: We describe 17 cases of REBOA within the DODTR from 2007 to 2023, adding to the limited documentation of patients undergoing REBOA in military settings. We identified patterns of injury in line with previous studies of patients undergoing REBOA in military settings. In this small sample of military casualties, we observed a high survival rate.
Aging is a natural and multifactorial process associated with various physiological and behavioral changes. Some of these changes can lead to increased physical inactivity, resulting in declines in functionality and increased vulnerability to diseases. During acute hospitalization, one of the several clinical consequences is excessive bedrest, even when walking is possible. Which leads to functional decline, defined as iatrogenic nosocomial disability. The literature already well describes that a multicomponent physical exercise program improves functional and cognitive capacity in frail, institutionalized, or hospitalized old people. However, a program based on this model has not yet been implemented during short-term hospitalization in Brazil. Therefore, this study aims to evaluate the effects of a multicomponent program on functional performance and cognitive function in elderly individuals with different conditions of frailty during acute hospitalization at the "Hospital de Clínicas de Porto Alegre". Functional performance will be assessed using the Short Physical Performance Battery, Timed Up and Go, 6-meter gait velocity, handgrip strength, and muscle power in 3-times-sit-to-stand. Cognitive performance will be evaluated through the Mini-Mental State Examination, Geriatric Depression Scale-15, and part "A" of the Trail Making Test. Affectiveness of the intervention will be measured using the Affectivity Scale. Participants will be randomized into two groups: multicomponent training based on VIVIFRAIL (MT) and control group. Participants in both groups will receive usual hospital treatments, including physiotherapy sessions in the morning. Participants in the MT group will perform the exercise program adjusted to their frailty and with progressive volume in the afternoon. On hospital discharge day, patients will be re-evaluated. Statistical analysis will be conducted using Generalized Estimating Equations, adopting group and time factors with two stratifications. Post-hoc LSD tests will be used to identify differences between groups. Analyses will be performed both per protocol, for individuals who complete the study, and by intention-to-treat, including those who do not complete the protocol. Results will be considered significant when p ≤ 0.05 and presented as percentage change and standard deviation with a 95% confidence interval.
PROBLEM TO BE SOLVED: To provide a cosmetic having profitable bioactivation such as moisture-retaining activities and capable of manifesting excellent effect, etc., for improving roughened skin by including primeverose. SOLUTION: This cosmetic includes primeverose preferably of 0.01-20 wt.%. The primeverose is disaccharide having hydroxyl group at 6-position of Β-D- glucopyranose bonded to the hydroxyl group at 1-position of the xylose, for instance, preferably, synthesized by condensing D glucose with xylobiose in the presence of an enzyme such as pectinase. The cosmetic is preferably applied to the skin. A moisture-retaining component (for instance, sodium hyaluronate) different form the primeverose is included in the cosmetic, and further, an arbitrary component usually used for the cosmetic can be included as the constituting component. As the result, the undesirable situation with roughened skin, wrinkle, flabbiness, etc., can be expected to be improved.
Nanoparticles can be useful for delivering therapeutic agents, such as anticancer agents to diseased cells. The nanoparticles include a carrier polypeptide and a cargo, which can be bind through electrostatic interactions to form a nanoparticle composition. An exemplary composition comprises nanoparticles comprising a carrier polypeptide comprising a penton base segment and a binding segment: and a polypeptide cargo comprising a tag segment that binds to the binding segment of the carrier poly peptide through an electrostatic interaction. An exemplary carrier polypeptide comprises a person base segment and a negatively-charged binding segment, which can bind to a positively charged cargo. The carrier polypeptide can also include a cell-targeting segment which can target the nanoparticle to a cell. Compositions comprising nanoparticles can be administered to a subject for the treatment of disease, such as cancer.
G-protein coupled receptors are a diverse group that are the target of over 50% of marketed drugs. Activation of these receptors results in the exchange of bound GDP for GTP in the Gα subunit of the heterotrimeric G-protein. The Gα subunit dissociates from the β/γ subunits and both proceed to affect downstream signaling targets. The signal terminates by the hydrolysis of GTP to GDP and is regulated by Regulators of G-protein Signaling (RGS) proteins that act as GTPase Activating Proteins (GAPs). This makes RGS proteins potentially desirable targets for “tuning” the effects of current therapies as well as developing novel pharmacotherapies. The present invention provides a convenient assay for identifying modulators of RGS proteins that can be adapted for high throughput screening utilizing the colorimetric dye, malachite green, to detect free phosphate in the presence of a test compound.
Patients in this arm will receive the standard acute pain management regimen during hospital admission and will be sent home after discharge with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
BACKGROUND: Cerebral palsy (CP) is a clinical diagnosis and was long categorized as an acquired disorder, but more and more genetic etiologies are being identified. This review aims to identify the clinical characteristics that are associated with genetic CP to aid clinicians in selecting candidates for genetic testing.
METHODS: The PubMed database was systematically searched to identify genes associated with CP. The clinical characteristics accompanying these genetic forms of CP were compared with published data of large CP populations resulting in the identification of potential indicators of genetic CP.
RESULLTS: Of 1930 articles retrieved, 134 were included. In these, 55 CP genes (described in two or more cases, n = 272) and 79 candidate genes (described in only one case) were reported. The most frequently CP-associated genes were PLP1 (21 cases), ARG1 (17 cases), and CTNNB1 (13 cases). Dyskinesia and the absence of spasticity were identified as strong potential indicators of genetic CP. Presence of intellectual disability, no preterm birth, and no unilateral distribution of symptoms were classified as moderate genetic indicators.
CONCLUSIONS: Genetic causes of CP are increasingly identified. The clinical characteristics associated with genetic CP can aid clinicians regarding to which individual with CP to offer genetic testing. The identified potential genetic indicators need to be validated in large CP cohorts but can provide the first step toward a diagnostic algorithm for genetic CP.